Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etoposide + temozolomide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination chemotherapy regimen consisting of etoposide (a topoisomerase II inhibitor) and temozolomide (an alkylating agent). Both drugs penetrate the blood-brain barrier and have shown activity against brain tumors. The combination leverages their different mechanisms of action and the convenience of oral administration, allowing for outpatient treatment.
- Other names
- TMZ + VP-16TE
02
Targets
TOP2B (DNA topoisomerase II beta)TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on etoposide + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etoposide + temozolomide.